Sangui Biotech International, Inc. reported earnings results for the fiscal year 2018. For the period, the company reported revenues from royalty income and product sales of USD 77,152. In the same period of the previous year the comparable revenue amounted to USD 67,653. Due to increased revenues of the wound spray Granulox, the resulting royalty income of 2018 increased by 14% compared to previous year. Operating loss decreased compared to the prior year by USD 108,754 to USD 208,045.